Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2021 | Personalized medicine: an important step in the management of MS

Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, explains how treatment for multiple sclerosis may be personalized and the benefits of doing so. Available treatments vary in terms of their benefits and side effects; personalized treatment is essential for optimal treatment selection. Personalization takes into account biomarkers, such as blood markers and prognosis factors, including age and comorbidities. It also considers the expectations of the patient and their preferences, this is important to ensure patient cooperation and therefore to improve treatment efficacy. It is important to note that treatment may evolve with the changing circumstances of the patient. This interview took place during the European Academy of Neurology 2021 congress.

Disclosures

C.Oreja-Guevara has received speaker and consultation fees from Biogen Idec, Celgene, Sanofi-Genzyme, Novartis, Roche, Merck, and Teva.

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.